Express News | 2Seventy Bio : Abecma Generated About $54 Million in U.S. Revenue in Q2

ReutersJul 26 07:19 ET

Broker Revenue Forecasts For 2seventy Bio, Inc. (NASDAQ:TSVT) Are Surging Higher

Yahoo FinanceJul 4 14:24 ET

Novo Nordisk Buys 2seventy's Hemophilia A Program, Divestiture Supports Exclusive Focus On Abecma

BenzingaJun 27 13:17 ET

2seventy Bio Completes $40m Haemophilia A Program Deal With Novo Nordisk

Yahoo FinanceJun 27 13:02 ET

Express News | Wedbush Reiterates Neutral on 2seventy Bio, Maintains $5 Price Target

BenzingaJun 27 09:41 ET

2seventy bio (TSVT.US) rose nearly 4% in pre-market trading! Its type A hemophilia project was acquired by Novo Nordisk A/S (NVO.US).

Zhītōng Cáijīng APP learned that 2seventy bio (TSVT.US) has announced the completion of an assets purchase agreement. According to the agreement, Novo Nordisk (NVO.US) will acquire 2seventy bio's type A hemophilia project. In addition, Novo Nordisk will also acquire the rights to 2seventy bio's in-body gene editing technology. This technology is used for autologous or allogeneic cell therapy of immune cells for the treatment of autoimmune diseases. 2seventy bio also stated that the team currently involved in this project will join Novo Nordisk and...

Zhitong FinanceJun 27 08:21 ET